Palmer, B. F., Tumlin, J. A., Radhakrishnan, J., Rehaume, L. M., Cross, J. L., & Huizinga, R. B. (2025). The kidney injury biomarker profile of patients with lupus nephritis remains unchanged with the second-generation calcineurin inhibitor voclosporin. Frontiers in Nephrology, 5. https://doi.org/10.3389/fneph.2025.1540471

Dardik, G., Krieger, A., Rao, M. K., Stokes, M. B., Wooden, B., & Bomback, A. S. (2025). A Case Report and Literature Review of ANCA-Associated Vasculitis and Lupus Nephritis Overlap: Lessons in Management. Glomerular Diseases, 5(1), 168–175. Portico. https://doi.org/10.1159/000543014

Nielsen, W., Kharouf, F., Grajales, C. M., Thayaparan, A., Anderson, M., Strand, V., Simon, L., Bonilla, D., Morand, E., Thumboo, J., Aringer, M., Mosca, M., Bruce, I., Papadopoulos, E. J., Torralba, K. D., Whitall-Garcia, L. P., Rosen, C. F., Parodis, I., Kim, A., … Touma, Z. (2025). Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set. Seminars in Arthritis and Rheumatism, 72, 152684. https://doi.org/10.1016/j.semarthrit.2025.152684

Joyce, D. P., Berger, J. S., Guttmann, A., Hasan, G., Buyon, J. P., Belmont, H. M., Salmon, J., Askanase, A., Bathon, J., Geraldino-Pardilla, L., Ali, Y., Ginzler, E. M., Putterman, C., Gordon, C., Helmick, C. G., Barbour, K. E., Gold, H. T., Parton, H., & Izmirly, P. M. (2024). Prevalence of cardiovascular events in a population-based registry of patients with systemic lupus erythematosus. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-024-03395-6

Fleischer, S., Nash, T. R., Tamargo, M. A., Lock, R. I., Venturini, G., Morsink, M., Graney, P. L., Li, V., Lamberti, M. J., Liberman, M., Kim, Y., Tavakol, D. N., Zhuang, R. Z., Whitehead, J., Friedman, R. A., Soni, R. K., Seidman, J. G., Seidman, C. E., Geraldino-Pardilla, L., … Vunjak-Novakovic, G. (2024). An engineered human cardiac tissue model reveals contributions of systemic lupus erythematosus autoantibodies to myocardial injury. Nature Cardiovascular Research, 3(9), 1123–1139. https://doi.org/10.1038/s44161-024-00525-w

Tang, W., Marone, A., Khalili, L., Wang, X., Murray, S., Inzerillo, S., Bardien, M., Gaikwad, V., Kim, S., Geraldino-Pardilla, L., Hielscher, A., & Askanase, A. (2024). 616 Comparison of optical and ultrasound imaging in lupus arthritis. Epidemiology & Outcomes. https://doi.org/10.1136/lupus-2023-lupus21century.45

Askanase, A. D., Furie, R. A., Dall’Era, M., Bomback, A. S., Schwarting, A., Zhao, M.-H., Bruce, I. N., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R. A., van Vollenhoven, R., & Urowitz, M. B. (2024). Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations. Lupus Science & Medicine, 11(1), e001124. https://doi.org/10.1136/lupus-2023-001124

Kim, G., Levy, D. M., Nicolson, D., Minn, S., Knight, A., Hiraki, L. T., Lynch, A., Jean-St-Michel, E., Ashkanase, J., & Jeewa, A. (2024). Severe Inflammatory Heart Disease in Children With Lupus: A Case Series. CJC Pediatric and Congenital Heart Disease. https://doi.org/10.1016/j.cjcpc.2024.05.005

Yap, E., Askanase, A., Kalunian, K., Dall’era, M., Hodge, L., Truman, M., & Solomons, N. (2024). #468 Voclosporin-based, triple-immunosuppressive therapy vs high-dose glucocorticoid-based dual-immunotherapy for lupus nephritis: a propensity analysis. Nephrology Dialysis Transplantation, 39(Supplement_1). https://doi.org/10.1093/ndt/gfae069.136

Zanoni, F., Naesens, M., Leal, R., Amoroso, A., Caliskan, Y., Keating, B., Gharavi, A., Castellano, G., Batal, I., & Kiryluk, K. (2024). #1450 Polygenic risk score of native IgA nephropathy predicts risk of post-transplant disease recurrence. Nephrology Dialysis Transplantation, 39(Supplement_1). https://doi.org/10.1093/ndt/gfae069.184

Krustev, E., Hanly, J. G., Chin, R., Buhler, K. A., Urowitz, M. B., Gordon, C., Bae, S.-C., Romero-Diaz, J., Sánchez-Guerrero, J., Bernatsky, S., Wallace, D. J., Isenberg, D., Rahman, A., Merrill, J. T., Fortin, P. R., Gladman, D. D., Bruce, I. N., Petri, M. A., Ginzler, E. M., … Choi, M. Y. (2024). Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus. Lupus Science & Medicine, 11(1), e001139. https://doi.org/10.1136/lupus-2023-001139

Khalili, L., Kukafka, R., Weiner, J., Inzerillo, S., Tang, W., Geraldino-Pardilla, L., Schmidt, N., Gartshteyn, Y., Alvarez, K., & Askanase, A. (2024). Development of The Lupus Clinical Trials Enrollment Decision Aid: a pilot study. Frontiers in Lupus, 2. https://doi.org/10.3389/flupu.2024.1373534

Gartshteyn, Y., Geraldino-Pardilla, L., Khalili, L., Bukhari, S., Lerrer, S., Winchester, R. J., Askanase, A. D., & Mor, A. (2024). SAP-expressing T peripheral helper cells identify systemic lupus erythematosus patients with lupus nephritis. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1327437

Dall’Era, M., Kalunian, K., Askanase, A., Solomons, N., Truman, M., Hodge, L., & Yap, E. (2024). P87 Comparison of a voclosporin-based, triple immunotherapy regimen to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV plus AURORA 1 studies and ALMS. Poster Presentations, A104.2-A105. https://doi.org/10.1136/lupus-2024-el.141

Askanase, A. D., Dall’Era, M., & Almaani, S. (2024). Insights into future management of lupus nephritis. Frontiers in Lupus, 2. https://doi.org/10.3389/flupu.2024.1334932

Zureigat, H., Civieri, G., Abohashem, S., Osborne, M. T., Solomon, D. H., Giles, J. T., Bathon, J., Massarotti, E., Unizony, S., & Tawakol, A. (2024). Improvement in joint inflammation is accompanied by reduction in arterial inflammation: Tocilizumab in rheumatoid arthritis. Journal of Nuclear Cardiology, 33, 101813. https://doi.org/10.1016/j.nuclcard.2024.101813

Lee, J.-Y. (Esther), Mendel, A., Askanase, A., Bae, S.-C., Buyon, J., Clarke, A. E., Costedoat-Chalumeau, N., Fortin, P. R., Gladman, D., Ramsey-Goldman, R., Hanly, J. G., Inanç, M., Isenberg, D., Mak, A., Mosca, M., Petri, M., Rahman, A., Sanchez-Guerrero, J., Urowitz, M., … Vinet, É. (2023). LSO-083 ‘Systemic lupus erythematosus women with lupus nephritis in pregnancy therapeutic challenge (SWITCH)’: the systemic lupus international collaborating clinics experience. Short Oral Presentation. https://doi.org/10.1136/lupus-2023-kcr.124

Connelly, K., Eades, L., Koelmeyer, R., Ayton, D., Golder, V., Kandane-Rathnayake, R., Gregory-Wong, K., Brunner, H., Burke, L., Arnaud, L., Askanase, A., Aranow, C., Vital, E., Pons-Estel, G., Dantata, K., Sun, Y., Tanaka, Y., Lee, S., Lahoud, Y., … Morand, E. (2023). LO-033 Towards a novel clinical outcome assessment for systemic lupus erythematosus trials – first outcomes of an international consensus process. Oral Presentation. https://doi.org/10.1136/lupus-2023-kcr.34

Askanase, A. D., Aranow, C., Kim, M. Y., Kamen, D. L., Arriens, C., Khalili, L., Tang, W., Barasch, J., Dall’Era, M., & Mackay, M. (2023). Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE. Lupus Science & Medicine, 10(2), e000952. https://doi.org/10.1136/lupus-2023-000952

Askanase, A., Furie, R., Dall’era, M., Bomback, A., Schwarting, A., Zhao, M. H., Bruce, I. N., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R., Van Vollenhoven, R., & Urowitz, M. B. (2023). POS1153 APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENTS FROM THE PUBLISHED LITERATURE. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.3052

Askanase, A., Furie, R., Dall’era, M., Bomback, A., Schwarting, A., Zhao, M. H., Bruce, I. N., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R., Van Vollenhoven, R., & Urowitz, M. B. (2023). AB0531 APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO LUPUS NEPHRITIS TREATMENTS FROM THE PUBLISHED LITERATURE. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.3897

Askanase, A., Stach, C., Brittain, C., Stojan, G., & Furie, R. (2023). POS0115 DAPIROLIZUMAB PEGOL EFFICACY BY SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A POST HOC ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.1991

Mehta, B., Jannat-Khah, D., Glaser, K. K., Luo, Y., Sammaritano, L. R., Branch, D. W., Goodman, S. M., Lockshin, M., Wang, F., Ibrahim, S., & Salmon, J. E. (2023). Fetal and maternal morbidity in pregnant patients with Lupus: a 10-year US nationwide analysis. RMD Open, 9(1), e002752. https://doi.org/10.1136/rmdopen-2022-002752

Zuo, Y., Navaz, S., Liang, W., Li, C., Ayers, C. R., Rysenga, C. E., Harbaugh, A., Norman, G. L., Solow, E. B., Bermas, B., Akinmolayemi, O., Rohatgi, A., Karp, D. R., Knight, J. S., & de Lemos, J. A. (2023). Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events. JAMA Network Open, 6(4), e236530. https://doi.org/10.1001/jamanetworkopen.2023.6530

Askanase, A. D., Tang, W., Zuraw, Q., Gordon, R., Brotherton, B., & Merrill, J. T. (2023). Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE. Lupus Science & Medicine, 10(1), e000875. https://doi.org/10.1136/lupus-2022-000875

Solomon, D. H., Giles, J. T., Liao, K. P., Ridker, P. M., Rist, P. M., Glynn, R. J., Broderick, R., Lu, F., Murray, M. T., Vanni, K., Santacroce, L. M., Abohashem, S., Robson, P. M., Fayad, Z., Mani, V., Tawakol, A., & Bathon, J. (2022). Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 82(3), 324–330. https://doi.org/10.1136/ard-2022-223302

Askanase, A., Furie, R., DallEra, M., Bomback, A., Schwarting, A., Zhao, M.-H., Bruce, I., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R. A., Vollenhoven, R. van, Urowitz, M., & David, N. (2023). APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENTS FROM THE PUBLISHED LITERATURE. Congresso Brasileiro de Reumatologia, 1. https://doi.org/10.47660/cbr.2023.2501

Becker, Y. L., Boilard, É., Rollet-Labelle, E., Lood, C., Julien, A.-S., Leclerc, J., Lévesque, T., Urowitz, M., Hanly, J., Gordon, C., Bae, S.-C., Romero-Diaz, J., Sanchez-Guerrero, J., Clarke, A. E., Bernatsky, S., Wallace, D., Isenberg, D., Rahman, A., Merrill, J., … Fortin, P. R. (2022). 103 Exploratory segregation of patients upon their levels of anti- mitochondrial antibodies (AMAs) reveals associations between AMAs and disease manifestations. Lupus 21st Century 2022. https://doi.org/10.1136/lupus-2022-lupus21century.3

Almeida-Brasil, C. C., Hanly, J. G., Urowitz, M., Clarke, A. E., Ruiz-Irastorza, G., Gordon, C., Ramsey-Goldman, R., Petri, M. A., Ginzler, E. M., Wallace, D. J., Bae, S.-C., Romero-Diaz, J., Dooley, M.-A., Peschken, C., Isenberg, D., Rahman, A., Manzi, S., Jacobsen, S., Lim, S. S., … Bernatsky, S. (2022). Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine. Lupus Science & Medicine, 9(1), e000789. https://doi.org/10.1136/lupus-2022-000789

Ugarte-Gil, M. F., Hanly, J., Urowitz, M., Gordon, C., Bae, S.-C., Romero-Diaz, J., Sanchez-Guerrero, J., Bernatsky, S., Clarke, A. E., Wallace, D. J., Isenberg, D. A., Rahman, A., Merrill, J. T., Fortin, P. R., Gladman, D. D., Bruce, I. N., Petri, M., Ginzler, E. M., Dooley, M. A., … Alarcón, G. S. (2022). Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 81(11), 1541–1548. https://doi.org/10.1136/ard-2022-222487

Dei Zotti, F., Moriconi, C., Qiu, A., Miller, A., & Hudson, K. E. (2022). Distinct CD4+ T cell signature in ANA-positive young adult patients. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.972127

Cardwell, F. S., Elliott, S. J., Chin, R., St Pierre, Y., Choi, M. Y., Urowitz, M. B., Ruiz-Irastorza, G., Bernatsky, S., Wallace, D. J., Petri, M. A., Manzi, S., Bae, S.-C., Shin, J.-M., Mak, A., Cho, J., Peschken, C. A., Ramsey-Goldman, R., Fortin, P. R., Hanly, J. G., … Clarke, A. E. (2022). Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic. Lupus Science & Medicine, 9(1), e000755. https://doi.org/10.1136/lupus-2022-000755

Floege, J., Gibson, K. L., Praga, M., Radhakrishnan, J., Reich, H. N., Schreuder, M. F., Wetzels, J. F., Tesař, V., Vivarelli, M., Biechele, S., & Tonelli, M. (2022). Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey. Kidney International Reports, 7(9), 2081–2085. https://doi.org/10.1016/j.ekir.2022.06.010

BAHGAT, J., KHALEEL, A., LI, L., ALVAREZ, G., VOLPICELLI, E., & NEWMAN, R. (2022). A HISTOLOGICAL DIAGNOSIS OF CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME. Chest, 161(6), A182. https://doi.org/10.1016/j.chest.2021.12.214

Petri, M. A., Bertsias, G., Daniels, M., Fox, N. L., Hahn, B. H., Hammer, A., Harris, J., Quasny, H., Tani, C., & Askanase, A. (2022). POS0183 THE EFFECT OF BELIMUMAB ON SRI-4 RESPONSE IN MULTIPLE SUBGROUPS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A LARGE INTEGRATED ANALYSIS. Annals of the Rheumatic Diseases, 81, 323. https://doi.org/10.1136/annrheumdis-2022-eular.1807

Almeida-Brasil, C. C., Hanly, J. G., Urowitz, M., Clarke, A. E., Ruiz-Irastorza, G., Gordon, C., Ramsey-Goldman, R., Petri, M., Ginzler, E. M., Wallace, D. J., Bae, S.-C., Romero-Diaz, J., Dooley, M. A., Peschken, C., Isenberg, D., Rahman, A., Manzi, S., Jacobsen, S., Lim, S., … Bernatsky, S. (2022). Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 81(3), 370–378. https://doi.org/10.1136/annrheumdis-2021-221295

Steers, N. J., Gupta, Y., D’Agati, V. D., Lim, T. Y., DeMaria, N., Mo, A., Liang, J., Stevens, K. O., Ahram, D. F., Lam, W. Y., Gagea, M., Nagarajan, L., Sanna-Cherchi, S., & Gharavi, A. G. (2022). GWAS in Mice Maps Susceptibility to HIV-Associated Nephropathy to the Ssbp2 Locus. Journal of the American Society of Nephrology, 33(1), 108–120. https://doi.org/10.1681/asn.2021040543